← All trials
NCT07058545
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2021
- Primary completion
- Feb 20, 2023
- Completion date
- Feb 20, 2023
- First posted
- Jul 10, 2025
- Last posted
- Jul 10, 2025
- Enrollment
- 474
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ConjuChem Biotechnologies Inc.Lead sponsor
- Peking UniversityOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.